GE Healthcare’s Life Sciences business, a global provider of technologies and expertise to the biopharmaceutical and life sciences industries and Sealed Air Corporation, a global manufacturer of primary films for pharmaceutical solutions, today announced the expansion of a strategic alliance designed to further the development and innovation in the biopharmaceuticals industry.
The agreement marks the next stage of a long-term collaboration between GE and Sealed Air, following a successful research and development agreement which created a new film suitable for use across GE’s full Single-Use portfolio, exceptional superior cell growth, application robustness, and enhancing security of supply.
Morgan Norris, GM of Upstream Products at GE Healthcare’s Life Sciences business commented, “GE and Sealed Air share a vision of the importance of robust high quality films in the efficient manufacturing of life saving medicines such as monoclonal antibodies, vaccines and next generation biotherapeutics. Through this agreement we are confident that we will deliver the next level of purposefully constructed and manufactured films for bioprocessing applications, enabling improved performance, supply chain control, and material/supplier transparency that the market demands of Single-Use suppliers.”
Gareth Crain, Vice President and General Manager of Sealed Air’s Medical Applications division added, “The combination of GE’s industry knowledge and breadth of product portfolio, with our experience, established proven compliance and quality systems in the pharmaceutical market space will enable us to deliver film solutions uniquely suited to the needs of Single-Use technology. This agreement provides a great platform for us to leverage our expertise in polymers, pharmaceutical regulatory and in-market requirements. We have been present in the parenteral market for many years where our Nexcel® M312 film is considered to be best in class for IV solutions.”
